CEACAM5 and breast carcinoma: In our study population of 432 subjects of breast cancer, the median follow-up time was 80 months (range from 6 months to 118 months), elevated CEA and CA 15–3 levels were significantly associated with DFS and OS of breast cancer patients (Table 2 and Fig 1).